#TeamAlterome
#TeamAlterome joined the #Curebound Cancer Challenge — helping raise $3.3M for cancer research at leading #SanDiego research institutions. We are proud to walk, run, and ride with our community that is working to end cancer as we know it. #OncSky
August 20, 2025 at 1:00 PM
To kick off back-to-school season in #SanDiego, #TeamAlterome joined @lifesciencecares.bsky.social‬ & @hopethroughhousing.bsky.social‬ for a backpack build to support students & families in our community. #Scisky #Oncsky
August 28, 2025 at 1:05 PM
Alterome runs smoothly thanks to Patty Quintana & Cailin Fredrickson! Their dedication and organization keep our team on track every day. We are grateful for all that you do! #TeamAlterome #AdministrativeProfessionalsDay
April 23, 2025 at 1:01 PM
#TeamAlterome is fresh off our time at #ASCO25 (@ascocancer.bsky.social)! We valued the time spent connecting with other leaders in #CancerResearch and discussing our two precision oncology clinical programs focused on #AKT and #KRAS. #OncSky
June 5, 2025 at 4:10 PM
#TeamAlterome is grateful for the San Diego community that consistently supports our team. As part of our commitment to giving back, earlier this month we participated in a beach clean-up, removing nearly 200 pounds of trash cluttering La Jolla Shores Beach. #OncSky
July 17, 2025 at 1:02 PM
#TeamAlterome is looking forward to participating in the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. Learn more: www.businesswire.com/news/home/20...
February 26, 2026 at 12:09 PM
Johanna Mylet has joined #TeamAlterome as Chief Financial Officer. Johanna joins Alterome from Poseida Therapeutics, where she served as CFO from 2021 until the company's acquisition by Roche in 2025, following successive roles as Controller, VP and SVP of Finance. Learn more: bwnews.pr/4xIA6Ev
September 8, 2026 at 11:11 AM
Leonardo Faoro, MD, MBA, a medical oncologist with 16 years of biotech industry experience, has joined #TeamAlterome as Chief Medical Officer to lead the on-going clinical development of our investigational Phase 1/1b precision oncology programs.

Learn more: www.businesswire.com/news/home/20...
February 2, 2026 at 3:00 PM